Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Y-mAbs Therapeutics (NASDAQ:YMAB) from a buy rating to a hold rating in a report published on Thursday, Zacks.com reports.

According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “

Other equities research analysts also recently issued research reports about the stock. Cowen reissued a buy rating on shares of Y-mAbs Therapeutics in a research report on Monday, July 1st. HC Wainwright reissued a buy rating and set a $40.00 price target (up previously from $36.00) on shares of Y-mAbs Therapeutics in a research report on Monday, June 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $31.40.

Shares of YMAB opened at $25.77 on Thursday. The company has a market capitalization of $923.23 million and a P/E ratio of -17.18. The company has a quick ratio of 9.04, a current ratio of 9.04 and a debt-to-equity ratio of 0.02. The firm has a 50 day moving average of $23.86 and a 200 day moving average of $22.97. Y-mAbs Therapeutics has a twelve month low of $15.17 and a twelve month high of $31.00.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.05). On average, sell-side analysts expect that Y-mAbs Therapeutics will post -2.09 EPS for the current year.

In related news, insider Thomas Gad sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $20.03, for a total value of $80,120.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Johan Wedell-Wedellsborg sold 168,244 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $27.57, for a total transaction of $4,638,487.08. The disclosure for this sale can be found here. Insiders have sold 202,244 shares of company stock valued at $5,395,787 in the last three months. 38.40% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of YMAB. BNP Paribas Arbitrage SA purchased a new stake in Y-mAbs Therapeutics in the first quarter worth approximately $38,000. Bank of Montreal Can purchased a new stake in Y-mAbs Therapeutics in the second quarter worth approximately $39,000. Bank of America Corp DE boosted its holdings in Y-mAbs Therapeutics by 3,056.5% in the fourth quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock worth $122,000 after purchasing an additional 5,838 shares during the last quarter. Deutsche Bank AG purchased a new stake in Y-mAbs Therapeutics in the fourth quarter worth approximately $191,000. Finally, Swiss National Bank purchased a new stake in Y-mAbs Therapeutics in the second quarter worth approximately $290,000. Institutional investors own 29.51% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Story: Google Finance Portfolio Workaround

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.